Table 4.
Patient characteristics at initiation of irinotecan treatment according to HPD status
| Total | HPD N=9 |
Non-HPD N=57 |
P value (Fisher's exact test) |
OR (adjusted) |
95% CI | P value |
| Sex | ||||||
| Male | 6 (88.9%) | 47 (82.5%) | 0.364 | |||
| Female | 3 (11.1%) | 10 (17.5%) | ||||
| Age | ||||||
| Median (range) | 64 (53–75) | 66 (41–77) | ||||
| Performance status (PS) | ||||||
| PS 0 | 1 (11.1%) | 8 (14.0%) | 1.000 | |||
| >1 | 8 (88.9%) | 49 (86.0%) | ||||
| Histological type | ||||||
| Intestinal | 4 (44.4%) | 33 (61.1%) | 1.000 | |||
| Diffuse | 5 (55.6%) | 21 (38.9%) | ||||
| HER2 status | ||||||
| Negative | 3 (50.0%) | 31 (72.1%) | 0.469 | |||
| Positive | 3 (50.0%) | 12 (27.9%) | ||||
| Disease status | ||||||
| Recurrent | 2 (22.2%) | 17 (29.8%) | 1.000 | Reference | ||
| Stage IV | 7 (77.8%) | 40 (70.2%) | 2.320 | 0.38 to 14.10 | 0.361 | |
| Peritoneal metastasis | ||||||
| Absent | 7 (77.8%) | 41 (71.9%) | 0.282 | |||
| Present | 2 (22.2%) | 16 (28.1%) | ||||
| No of metastatic sites | ||||||
| 1 | 2 (22.2%) | 12 (21.1%) | 1.000 | |||
| ≥2 | 7 (77.8%) | 45 (78.9%) | ||||
| No of prior chemotherapy lines | ||||||
| <3 | 9 (100%) | 53 (94.7%) | 1.000 | Reference | ||
| ≥3 | 0 (0%) | 4 (5.3%) | <0.0001 | 0.00 to Inf | 0.994 | |
| Agents contained in postchemotherapy | ||||||
| Fluoropyrimidine | 2 (22.2%) | 5 (8.8%) | 0.241 | |||
| Platinum | 2 (22.2%) | 4 (7.0%) | 0.186 | |||
| Taxane | 0 (0%) | 3 (5.3%) | 1.000 | |||
| Ramucirumab | 1 (11.1%) | 4 (7.0%) | 0.531 | |||
| Immune check point inhibitor | 0 (%) | 4 (7.0%) | 1.000 | |||
| ALP (U/L) | ||||||
| <360 | 7 (77.8%) | 31 (54.4%) | 0.282 | Reference | ||
| ≥360 | 2 (22.2%) | 26 (45.6%) | 0.215 | 0.04 to 1.26 | 0.09 | |
ALP, alkaline phosphatase; HPD, hyperprogressive disease.